Literature DB >> 18182998

The regulator disapproves.

.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18182998     DOI： 10.1038/nbt0108-1

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  5 in total

Review 1.  [Prostate carcinoma: vaccination as a new option for treatment].

Authors:  J Bedke; C Gouttefangeas; A Stenzl
Journal:  Urologe A       Date:  2012-01       Impact factor: 0.639

2.  Landmark approval for Dendreon's cancer vaccine.

Authors:  Laura DeFrancesco
Journal:  Nat Biotechnol       Date:  2010-06       Impact factor: 54.908

3.  Cancer immunotherapy products: regulatory aspects in the European Union.

Authors:  Jorge Camarero; Sol Ruiz
Journal:  Hum Vaccin Immunother       Date:  2012-08-06       Impact factor: 3.452

Review 4.  Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines.

Authors:  Tanja D de Gruijl; Alfons J M van den Eertwegh; Herbert M Pinedo; Rik J Scheper
Journal:  Cancer Immunol Immunother       Date:  2008-06-04       Impact factor: 6.968

5.  Challenges in the translation and commercialization of cell therapies.

Authors:  Brittany P Dodson; Aaron D Levine
Journal:  BMC Biotechnol       Date:  2015-08-07       Impact factor: 2.563
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.